Dr. Zheng Zhao 赵征
Chief Physician
Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of lung cancer, lymphoma, breast cancer, and gastrointestinal tumors. Focuses on targeted and immunotherapy for recurrent or refractory cases, using gene testing for efficacy assessment and recurrence monitoring in non-small cell lung cancer and other solid tumors.
Dr. Zhao holds a PhD in Oncology from Fourth Military Medical University and serves as Deputy Director of Internal Medicine at Shaanxi Provincial Cancer Hospital. A visiting scholar at the German SANA Cancer Center and Cancer Hospital of the Chinese Academy of Medical Sciences, Dr. Zhao specializes in clinical diagnosis, research, and comprehensive treatment of various malignancies.
Professional roles
- Vice Director, Lung Nodule Diagnosis and Treatment Sub-center, China Lung Cancer Prevention and Control Alliance
- Vice Chair, Tumor Marker Professional Committee, China Anti-Cancer Association
- Vice Chair, Chemotherapy Drug Professional Committee, Shaanxi Health Care Association
- Standing Committee Member, Minimally Invasive Treatment Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhao Zheng). Papers usually list the name as Zheng Zhao or Zhao Z.
Selected publications
17 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Rep, 2026 (senior author): Recapitulating lung cancer metastasis in vitro: Advances in organoid models and challenges in clinical translation (Review). PubMed 41574717
- Cancer Med, 2025 (first author): Molecular Characteristics and Treatment Implications of TP53 Gain-of-Function Mutations in Non-Small Cell Lung Cancer. PubMed 41128012
- Front Oncol, 2025 (senior author): Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion. PubMed 40900786
- Oncol Lett, 2025 (senior author): Immunotherapy for primary squamous cell carcinoma of the liver: A case report. PubMed 40242270
- Oncol Lett, 2024 (senior author): Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review). PubMed 39319213
- Respir Res, 2023 (senior author): Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. PubMed 36698189
- J Biomed Nanotechnol, 2022 (senior author): The Treatment of Human Colon Xenografts Tumor in Mice with Platinum Nanosphere-5-Fluorouracil-Bovine Albumin. PubMed 35715920
- J Med Genet, 2020 (first author): Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. PubMed 32284345
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion